Description
The prevalence of cardiovascular disease in China impacted by accelerated aging of population and changes in consumption concept, dietary habit, way of working and other lifestyles has been growing year after year, thereby promoting the development of domestic percutaneous coronary intervention (PCI) market. PCI cases in China totaled 454,505 in 2013, up 16.9% from a year earlier; meanwhile the interventional cardiovascular device industry there was worth RMB20.12 billion.
View Full Report At: http://www.marketresearchreports.biz/analysis/225127
At present, half of the Chinese interventional cardiovascular device industry is dominated by domestic companies led by MicroPort, Lepu Medical, Lifetech Scientific, and Dalian Yinyi. In 2013, 53.4% of the Chinese market was controlled by domestic companies, 31.2% by foreign counterparts represented by Johnson & Johnson, Medtronic, Boston Scientific, Abbott, B. Braun and Terumo, and 15.4% by those invested by Hong Kong, Macao and Taiwan.
Interventional cardiovascular devices in China include cardiovascular stent, catheter, guidewire, balloon, surgical auxiliary devices, etc., among which cardiovascular stent is predominant.
Download Sample Of This Report: http://www.marketresearchreports.biz/sample/sample/225127
Cardiovascular stent: In 2013, the Chinese cardiovascular stent market equaled RMB11.2 billion, 78.8% of which was occupied by domestic drug-eluting stents. That same year, 686,000 units of cardiovascular stent were consumed in China, up 11.7% year on year, and drug-eluting stents accounted for 99.5%, indicating that the drug-eluting stent is gradually becoming an important device for interventional cardiovascular therapy.
In addition, Abbott has developed biodegradable stents, which are sold in Europe; Lepu Medical is endeavoring to develop biodegradable stents, which are expected to be available on the market in 2017. Thanks to its excellent performance, biodegradable stents are likely to replace drug-eluting stents gradually in the future, thus becoming the main variety in domestic coronary stent market.
Balloon catheter: In 2013, China’s demand for PTCA balloon catheter amounted to 1.186 million units, 500,000 of which were PTCA balloon catheters for dilatation. With rapid development of local PTCA balloon catheter producers represented by Lepu Medical, MicroPort and JW Medical, domestic PTCA balloon catheters increased its market share from 20% in 2009 to 40% in 2013.
Affected by the implementation of “Regulations on the Centralized Procurement of High-value Medical Consumables”, purchase price of interventional cardiovascular devices will continue to decline, further squeezing profit margins of relevant companies. However, the substantial decline in prices will enable more patients to receive PCI, thus helping the industry maintain a fairly rapid growth rate. It is expected that the Chinese interventional cardiovascular device market will worth RMB41.2 billion by 2017.
Table of Content
1. Overview of Interventional Cardiovascular Device Industry
1.1 Definition
1.2 Classification and Application of Products
1.3 Industry Chain
2. Status Quo of China Interventional Cardiovascular Device Industry
2.1 Overview
2.2 Market Demand
2.3 Import & Export
2.4 Competitive Landscape
2.5 Entry Barriers
2.5.1 Technology
2.5.2 Talent
2.5.3 Patent
2.5.4 Policy
2.5.5 Market Channel
Related Reports
Global LVAD Market Report: 2013 Edition
View Full Report At: http://www.marketresearchreports.biz/analysis/176795
LVADs are the mechanical devices which are implanted into the abdomen or chest and attached to a weakened heart to help it pump. LVADs are now sometimes used as an alternative to transplantation. LVAD is suitable for bridge-to-transplant market, which extends the patient’s life until a suitable donor is found.
Download Sample Of This Report: http://www.marketresearchreports.biz/sample/sample/176795
The report examines the LVAD market on a global scale and its various segments. The use of bridge-to-transplant has been more than destination therapy and is expected to rise in coming years.
Intravascular Ultrasound (IVUS) Market Report - 2011 Edition
View Full Report At: http://www.marketresearchreports.biz/analysis/25982
IVUS, which stands for Intravascular Ultrasound, is primarily used to view the coronary arteries from inside, with the help of high frequency sound waves. The primary use of IVUS is during Percutaneous Coronary Intervention (PCI) or angioplasty, as it provides a better understanding of blocked vessels.
Download Sample Of This Report: http://www.marketresearchreports.biz/sample/sample/25982
In association with analyzing the global IVUS market, the current report also discusses the major regional markets, including Japan, US, and Europe.
About Us
MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.
Contact Us
Office: State Tower
90 Sate Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA: Canada Toll Free: 866-997-4948
Website: http://www.marketresearchreports.biz/
E: sales@marketresearchreports.biz
The prevalence of cardiovascular disease in China impacted by accelerated aging of population and changes in consumption concept, dietary habit, way of working and other lifestyles has been growing year after year, thereby promoting the development of domestic percutaneous coronary intervention (PCI) market. PCI cases in China totaled 454,505 in 2013, up 16.9% from a year earlier; meanwhile the interventional cardiovascular device industry there was worth RMB20.12 billion.
View Full Report At: http://www.marketresearchreports.biz/analysis/225127
At present, half of the Chinese interventional cardiovascular device industry is dominated by domestic companies led by MicroPort, Lepu Medical, Lifetech Scientific, and Dalian Yinyi. In 2013, 53.4% of the Chinese market was controlled by domestic companies, 31.2% by foreign counterparts represented by Johnson & Johnson, Medtronic, Boston Scientific, Abbott, B. Braun and Terumo, and 15.4% by those invested by Hong Kong, Macao and Taiwan.
Interventional cardiovascular devices in China include cardiovascular stent, catheter, guidewire, balloon, surgical auxiliary devices, etc., among which cardiovascular stent is predominant.
Download Sample Of This Report: http://www.marketresearchreports.biz/sample/sample/225127
Cardiovascular stent: In 2013, the Chinese cardiovascular stent market equaled RMB11.2 billion, 78.8% of which was occupied by domestic drug-eluting stents. That same year, 686,000 units of cardiovascular stent were consumed in China, up 11.7% year on year, and drug-eluting stents accounted for 99.5%, indicating that the drug-eluting stent is gradually becoming an important device for interventional cardiovascular therapy.
In addition, Abbott has developed biodegradable stents, which are sold in Europe; Lepu Medical is endeavoring to develop biodegradable stents, which are expected to be available on the market in 2017. Thanks to its excellent performance, biodegradable stents are likely to replace drug-eluting stents gradually in the future, thus becoming the main variety in domestic coronary stent market.
Balloon catheter: In 2013, China’s demand for PTCA balloon catheter amounted to 1.186 million units, 500,000 of which were PTCA balloon catheters for dilatation. With rapid development of local PTCA balloon catheter producers represented by Lepu Medical, MicroPort and JW Medical, domestic PTCA balloon catheters increased its market share from 20% in 2009 to 40% in 2013.
Affected by the implementation of “Regulations on the Centralized Procurement of High-value Medical Consumables”, purchase price of interventional cardiovascular devices will continue to decline, further squeezing profit margins of relevant companies. However, the substantial decline in prices will enable more patients to receive PCI, thus helping the industry maintain a fairly rapid growth rate. It is expected that the Chinese interventional cardiovascular device market will worth RMB41.2 billion by 2017.
Table of Content
1. Overview of Interventional Cardiovascular Device Industry
1.1 Definition
1.2 Classification and Application of Products
1.3 Industry Chain
2. Status Quo of China Interventional Cardiovascular Device Industry
2.1 Overview
2.2 Market Demand
2.3 Import & Export
2.4 Competitive Landscape
2.5 Entry Barriers
2.5.1 Technology
2.5.2 Talent
2.5.3 Patent
2.5.4 Policy
2.5.5 Market Channel
Related Reports
Global LVAD Market Report: 2013 Edition
View Full Report At: http://www.marketresearchreports.biz/analysis/176795
LVADs are the mechanical devices which are implanted into the abdomen or chest and attached to a weakened heart to help it pump. LVADs are now sometimes used as an alternative to transplantation. LVAD is suitable for bridge-to-transplant market, which extends the patient’s life until a suitable donor is found.
Download Sample Of This Report: http://www.marketresearchreports.biz/sample/sample/176795
The report examines the LVAD market on a global scale and its various segments. The use of bridge-to-transplant has been more than destination therapy and is expected to rise in coming years.
Intravascular Ultrasound (IVUS) Market Report - 2011 Edition
View Full Report At: http://www.marketresearchreports.biz/analysis/25982
IVUS, which stands for Intravascular Ultrasound, is primarily used to view the coronary arteries from inside, with the help of high frequency sound waves. The primary use of IVUS is during Percutaneous Coronary Intervention (PCI) or angioplasty, as it provides a better understanding of blocked vessels.
Download Sample Of This Report: http://www.marketresearchreports.biz/sample/sample/25982
In association with analyzing the global IVUS market, the current report also discusses the major regional markets, including Japan, US, and Europe.
About Us
MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.
Contact Us
Office: State Tower
90 Sate Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA: Canada Toll Free: 866-997-4948
Website: http://www.marketresearchreports.biz/
E: sales@marketresearchreports.biz
0 comments:
Post a Comment